Zealand Pharma and Helsinn announce the advance of elsiglutide into Phase II for the prevention of chemotherapy-induced diarrhea in cancer patients
First patients dosed in Phase IIa study of novel GLP-2 peptide agonist
The Phase IIa study is a randomized, double-blind and placebo-controlled proof-of-concept study to assess the efficacy and safety of elsiglutide for the prevention of chemotherapy-induced diarrhea (CID) in colorectal cancer patients receiving 5-fluorouracil (5-FU)-based chemotherapy. In the study, elsiglutide is administered subcutaneously in parallel with 5-FU. The Phase IIa study is conducted by Helsinn and plans to enroll 138 cancer patients in approximately 20 centers across European countries.
Helsinn is also completing a Phase Ib study of elsiglutide in Europe under an Investigational New Drug (IND) with the US Food and Drug Administration (FDA) so far showing that the drug candidate is safe and well tolerated at doses above the expected therapeutic dose in colorectal cancer patients.
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.